Application of an Antibody Biochip for p53 Detection and Cancer Diagnosis

Authors

  • Minoo Askari,

    1. Advanced Monitoring Development Group, Life Sciences Division, Oak Ridge National Laboratory, Oak Ridge, Tennessee 37831–6101
    2. Graduate School of Biomedical Sciences, University of Tennessee/Knoxville, Oak Ridge, Tennessee 37830–8026
    Search for more papers by this author
  • Jean Pierre Alarie,

    1. Advanced Monitoring Development Group, Life Sciences Division, Oak Ridge National Laboratory, Oak Ridge, Tennessee 37831–6101
    Search for more papers by this author
  • Maria Moreno-Bondi,

    1. Departmento de Quimica Analitica, Universidad Complutense, 28040 Madrid, Spain
    Search for more papers by this author
  • Tuan Vo-Dinh

    Corresponding author
    1. Advanced Monitoring Development Group, Life Sciences Division, Oak Ridge National Laboratory, Oak Ridge, Tennessee 37831–6101
    2. Graduate School of Biomedical Sciences, University of Tennessee/Knoxville, Oak Ridge, Tennessee 37830–8026
    • Advanced Monitoring Development Group, Oak Ridge National Laboratory, P.O. Box 2008, Oak Ridge, TN 37831–6101, USA. Tel: 865–574–6249. Fax: 865–576–7651
    Search for more papers by this author

Abstract

Detection of the p53 tumor suppressor gene is important in early cancer diagnostics because alterations in the gene have been associated with carcinogenic manifestations in several tissue types in humans. We have developed an antibody-based detection instrument, the biochip, to detect the presence of the anti-p53 antibody in human serum. The design of this highly integrated detector system is based on miniaturized phototransistors having multiple optical sensing elements, amplifiers, discriminators, and logic circuitry on an IC board. The system utilizes laser excitation and fluorescence signals to detect complex formation between the p53 monoclonal antibody and the p53 antigen. Recognition antibodies are immobilized on a nylon membrane platform and incubated in solutions containing antigens labeled with Cy5, a fluorescent cyanine dye. Subsequently, this membrane is placed on the detection platform of the biochip and fluorescence signal is induced using a 632.8-nm He-Ne laser. Using this immuno-biochip, we have been able to detect binding of the p53 monoclonal antibody to the human p53 cancer protein in biological matrices. The performance of the integrated phototransistors and amplifier circuits of the biochip, previously evaluated through measurement of the signal output response for various concentrations of fluorescein-labeled molecules, have illustrated the linearity of the microchip necessary for quantitative analysis. The design of this biochip permits sensitive, selective and direct measurements of a variety of antigen-antibody formations at very low concentrations. Furthermore, the acquisitions of the qualitative and quantitative results are accomplished rapidly, in about 15 min. These features demonstrate the potential of this antibody-based biochip for simple, rapid and early biomedical diagnostics of cancer.

Ancillary